Crown Laboratories And Revance Therapeutics Announce Merger To Create Leading High-Growth Aesthetics And Skincare Company
Portfolio Pulse from Benzinga Newsdesk
Crown Laboratories and Revance Therapeutics have announced a merger to create a leading high-growth aesthetics and skincare company. The merger will combine flagship brands such as DAXXIFY, RHA Collection, SkinPen, PanOxyl, Blue Lizard, and StriVectin, offering global commercialization potential and enhanced product development with an experienced leadership team.
August 12, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revance Therapeutics is merging with Crown Laboratories to form a leading high-growth aesthetics and skincare company. This merger is expected to enhance global commercialization and product development.
The merger is likely to positively impact Revance Therapeutics' stock price in the short term due to the potential for enhanced global commercialization and product development. The combination of flagship brands and an experienced leadership team adds to the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100